U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07358585) titled 'A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer' on Jan. 14.
Brief Summary: This study is a phase Ib/II study to evaluate the efficacy, safety and tolerance of HLX43 combined with HLX07 or Serplulimab in patients with advanced or metastatic colorectal cancer failed or intolerance to standard first-line therapy
Study Start Date: Jan. 31
Study Type: INTERVENTIONAL
Condition:
Colon Cancer Adenocarcinoma
Intervention:
DRUG: HLX43 dose 1 + HLX07
HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo...